Why carry out this study?

Because most patients with psoriatic arthritis (PsA) do not maintain minimal disease activity on current therapies, there is an unmet need for safe and effective long-term treatment.

This study reports the 100-week efficacy and safety results of the KEEPsAKE 1 study for patients with active PsA treated with risankizumab 150 mg every 12 weeks.

Patients enrolled in this study had previous inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug.

What was learned from the study?

At week 100, risankizumab demonstrated durable improvement in the signs and symptoms of PsA and was generally well tolerated with a stable safety profile.